首页> 外文期刊>Jurnalul Pediatrului >PROX1 IMMUNOHISTOCHEMICAL ANALYSIS OF PEDIATRIC VASCULAR ANOMALIES, A POSIBLE PROGNOSTIC AND THERAPEUTIC FACTOR OF HEMANGIOMAS?
【24h】

PROX1 IMMUNOHISTOCHEMICAL ANALYSIS OF PEDIATRIC VASCULAR ANOMALIES, A POSIBLE PROGNOSTIC AND THERAPEUTIC FACTOR OF HEMANGIOMAS?

机译:Prox1儿科血管异常的免疫组化分析,血管瘤的Posible预后和治疗因子吗?

获取原文
           

摘要

Infantile and congenital hemangiomas still a challenge for both the pediatric surgeon and the pediatrician.The treatment of hemangiomas must be individualized according to: the type of lesion, location, size, depth, stage of growth and evolution of the lesion.To date, none of the available therapies is considered standard therapy.Currently, personalized therapy is not widely applied in Romania, not being included in the usual therapy protocols in any of the types of hemangioma.This is a starting point for the identification of new specific therapeutic targets that preserve normal endothelial cells and determine the regression of hemangioma, especially recurrent ones and those with an increased proliferation rate.Another controversial and unexplained aspect, consequently unexploited from a therapeutic point of view is represented by the expression and role of lymphatic markers in infantile and congenital hemangiomas.
机译:婴儿和先天性血管瘤仍然是儿科外科医生和儿科医生的挑战。血管瘤的治疗必须根据:病变,位置,大小,深度,生长阶段和损伤演变的类型。迄今为止,无在可用的疗法被认为是标准治疗。,个性化治疗不广泛应用于罗马尼亚,未被包含在任何类型的血管瘤类型中的常规治疗方案中。这是鉴定新的特定治疗目标的起点保持正常的内皮细胞并确定血管瘤的回归,特别是复发性和增殖率增加的回归。另外有争议的和无法解释的方面,因此从治疗性观察结果是由婴儿和先天中的淋巴标志物的表达和作用表示的血管瘤。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号